Pfizer has set its FY2026 profit forecast below analyst estimates, blaming projected losses on waning Covid vaccine sales and the looming patent cliff faced by some of its best-selling assets. Through this adjustment, Pfizer now expects profits ranging between $2.80 and$3 per share in 2026, which sits below the analyst estimate of $3.05 per share, as per the London Stock Exchange (LSEG). This means the company now expects its FY2026 revenue to fall somewhere between$59.5bn and $62.5bn. This compares w ...